| Literature DB >> 28577672 |
Steven L Goldberg1, Ian Meredith2, Thomas Marwick3, Brian A Haluska4, Janusz Lipiecki5, Tomasz Siminiak6, Nawzer Mehta7, David M Kaye8, Horst Sievert9.
Abstract
The Carillon Mitral Contour System has been studied in 3 nonrandomized trials in patients with symptomatic congestive heart failure and functional mitral regurgitation. The REDUCE FMR study is a uniquely designed, double-blind trial evaluating the impact of the Carillon device on reducing regurgitant volume, as well as assessing the safety and clinical efficacy of this device. Carillon is a coronary sinus-based indirect annuloplasty device. Eligible patients undergo an invasive venogram to assess coronary sinus vein suitability for the Carillon device. If the venous dimensions are suitable, they are randomized on a 3:1 basis to receive a device or not. Patients and assessors are blinded to the treatment assignment. The primary end point is the difference in regurgitant volume at 1 year between the implanted and nonimplanted groups. Other comparisons include clinical parameters such as heart failure hospitalizations, 6-minute walk test, Kansas City Cardiomyopathy Questionnaire (KCCQ), and other echocardiographic parameters. An exercise echo substudy will also be included.Entities:
Mesh:
Year: 2017 PMID: 28577672 DOI: 10.1016/j.ahj.2017.02.032
Source DB: PubMed Journal: Am Heart J ISSN: 0002-8703 Impact factor: 4.749